A latest research report by IMARC group the titled is that “Pneumococcal Vaccine Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028”, offers a comprehensive analysis of the industry, which comprises insights on pneumococcal vaccine market size. The report also includes competitor and regional analysis, and contemporary advancements in the global market. The global pneumococcal vaccine market size reached US$ 8.9 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 12.2 Billion by 2028, exhibiting a growth rate (CAGR) of 5.2% during 2023-2028.

What are pneumococcal vaccine?

Pneumococcal vaccine represents medicinal therapies that offer protection against the bacterium Streptococcus pneumoniae. They can be broadly categorized into two types, including conjugate and polysaccharide. These pneumococcal vaccine variants stimulate the immune system and protect against the bacterial strains responsible for severe infections from meningitis, pneumonia, and sepsis. They prove effective for both children and adults. As a result, pneumococcal vaccine therapies are in extensively utilized across the globe.

Get a Free Sample Copy of this Report: https://www.imarcgroup.com/pneumococcal-vaccine-market/requestsample

What are the growth prospects and trends in the pneumococcal vaccine industry?

The increasing demand for specific medication for treating complications associated with pneumonia, such as breathing issues and fluid accumulation around lungs, etc., is primarily driving the pneumococcal vaccine market. Additionally, the elevating number of smokers, heavy drinkers, diabetes patients, and individuals with chronic health conditions, who are extremely vulnerable to illnesses and ailments owing to their weakened immune system, is acting as another significant growth-inducing factor. Furthermore, the introduction of Pneumococcal Conjugate Vaccine (PCV) in infant routine immunization and the launch of several policies by the government bodies to promote the application of this vaccine therapy are also positively influencing the market growth. Besides this, the rising focus among key market players in research and development (R&D) activities for formulating novel vaccine treatments and the inflating investments in healthcare infrastructure, especially in developing countries, are expected to fuel the pneumococcal vaccine market over the forecasted period.

View Full Report with TOC & List of Figure: https://www.imarcgroup.com/pneumococcal-vaccine-market

Competitive Landscape:

The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.

  • Astellas Pharma Inc.
  • GlaxoSmithKline Plc.
  • Merck & Co. Inc.
  • Panacea Biotec Ltd.
  • Pfizer Inc.
  • Sanofi S.A.
  • Serum Institute of India Pvt Ltd
  • Walvax Biotechnology Co. Ltd.

Pneumococcal Vaccine Market Segmentation:

Our report has categorized the market based on region, vaccine type, product type, distribution channel and end user.
Breakup by Vaccine Type:

  • Pneumococcal Conjugate Vaccine
  • Pneumococcal Polysaccharide Vaccine

Breakup by Product Type:

  • Prevnar 13
  • Synflorix
  • Pneumovax 23

Breakup by Distribution Channel:

  • Distribution Partner Companies
  • Non-Governmental Organizations (NGO)
  • Government Authorities

Breakup by End User:

  • Pediatrics
  • Adults

Breakup by Region:

  • North America (United States, Canada)
  • Europe (Germany, France, United Kingdom, Italy, Spain, Others)
  • Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
  • Latin America (Brazil, Mexico, Others)
  • Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Other)

Key highlights of the report:

  • Market Performance (2017-2022)
  • Market Outlook (2023-2028)
  • Porter’s Five Forces Analysis
  • Market Drivers and Success Factors
  • SWOT Analysis
  • Value Chain
  • Comprehensive Mapping of the Competitive Landscape

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: [email protected]
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe:- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800